4, 5, 6, 7 This increased incidence may in part be conducive to the increased survival of patients with EGFRm advanced NSCLC since the introduction of EGFR‐tyrosine kinase inhibitors (TKIs).8 Here, EGFR is linked to non-small cell lung carcinoma.